Arkolith/Stocks/Whitehawk Therapeutics, Inc.

Whitehawk Therapeutics, Inc.

Cross-source read

No active 13F manager changed its position in Whitehawk Therapeutics, Inc. last quarter. Over the last 180 days, 3 insiders sold and none bought, a net -$2.6M in open-market trades.

Tracked 13F holders
0
13F value (tracked)
$0
Smart-money readMixed
Net sellingNet buying
Funds · active managers, latest 13F
0 adding · 0 trimming
Insiders · Form 4 open-market, 180d
0 buying · 3 selling · -$2.6M
US House · STOCK Act, 180d
0 buying · 0 selling

The legs disagree, or only one of them leans.

Who owns Whitehawk Therapeutics, Inc.?

0 tracked 13F filers · ranked by shares held

Not held in any tracked 13F filing yet.

Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.

Insider activity (Form 4)

Full insider page →
Sells · 180d
$2.6M
3 insiders
Net · 180d
-$2.6M
11 open-market transactions
DateInsiderRoleActionSharesValue
Apr 16, 2026Giacobello Scott M.CHIEF FINANCIAL OFFICERSell (S)142K$585K
Apr 15, 2026Giacobello Scott M.CHIEF FINANCIAL OFFICERSell (S)77K$297K
Apr 14, 2026Ball BryanSee remarksSell (S)92K$337K
Apr 13, 2026Ball BryanSee remarksSell (S)26K$91K
Apr 10, 2026Ball BryanSee remarksSell (S)7K$23K
Apr 9, 2026Lennon David JamesCHIEF EXECUTIVE OFFICER, DirectorSell (S)15K$49K
Apr 9, 2026Ball BryanSee remarksSell (S)50K$179K
Apr 8, 2026Lennon David JamesCHIEF EXECUTIVE OFFICER, DirectorSell (S)64K$217K
Apr 7, 2026Lennon David JamesCHIEF EXECUTIVE OFFICER, DirectorSell (S)94K$323K
Apr 6, 2026Lennon David JamesCHIEF EXECUTIVE OFFICER, DirectorSell (S)102K$359K
Apr 2, 2026Lennon David JamesCHIEF EXECUTIVE OFFICER, DirectorSell (S)27K$93K
Mar 2, 2026Lennon David JamesCHIEF EXECUTIVE OFFICER, DirectorSell (S)5K$17K

Do institutions, insiders and Congress agree?

Mixed signals

Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.

SEC EDGAR 13F + Form 4 + US House STOCK Act{ }get_ticker_confluence · API & MCP

Signals by source

Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive

SourceBuyingSellingNet
13F funds
Top 100 holders by value, passive included; the hero counts active managers only
00–
Insiders
Form 4 open-market
03-$2.6M
US House
STOCK Act trades
00$0

Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.

Recent filings

15 most recent

Keep exploring

Connected entities for Whitehawk Therapeutics, Inc.

More on Whitehawk Therapeutics, Inc.

Browse more

All tracked stocks A–ZWhitehawk Therapeutics, Inc. insider filings13F funds A–Z
Build

Ask your agent what changed in Whitehawk Therapeutics, Inc.

This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.

Get a key Compare plansWorkflow docs
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/stocks/AADI/capital-change-brief"
Ask your agent
Use Arkolith's capital_change_brief for Whitehawk Therapeutics, Inc..
Tell me what changed, whether insider activity
corroborates it, and cite the SEC evidence.

13F holdings + Form 4 insider transactions + the live filing stream, joined for AADI. Filings are public domain, sourced to SEC EDGAR.